Connection
Robin Deterding to Purinergic P2 Receptor Agonists
This is a "connection" page, showing publications Robin Deterding has written about Purinergic P2 Receptor Agonists.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.319 |
|
|
|
-
Deterding R, Retsch-Bogart G, Milgram L, Gibson R, Daines C, Zeitlin PL, Milla C, Marshall B, Lavange L, Engels J, Mathews D, Gorden J, Schaberg A, Williams J, Ramsey B. Safety and tolerability of denufosol tetrasodium inhalation solution, a novel P2Y2 receptor agonist: results of a phase 1/phase 2 multicenter study in mild to moderate cystic fibrosis. Pediatr Pulmonol. 2005 Apr; 39(4):339-48.
Score: 0.247
-
Deterding RR, Lavange LM, Engels JM, Mathews DW, Coquillette SJ, Brody AS, Millard SP, Ramsey BW. Phase 2 randomized safety and efficacy trial of nebulized denufosol tetrasodium in cystic fibrosis. Am J Respir Crit Care Med. 2007 Aug 15; 176(4):362-9.
Score: 0.071